Biosimilars – Forecast – Forecast Methodology and General Market Assumptions
In 2022, sales of branded biologics for oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology indications exceeded $150 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Sales of biosimilars in these therapy areas and countries totaled approximately $13 billion. Throughout our 2022-2032 forecast period, increasing numbers of branded biologics are set to lose patent protection, and we expect biosimilars to enter the market and erode both patient share and drug prices. We present our forecasts for key reference brands and their biosimilars by therapeutic area, molecule, and country / region.
Table of contents
Yashu Malhotra, M.Pharm., is an analyst on the Biosimilars and Oncology teams at Clarivate. Previously, she was a senior analyst in the life sciences department at Course5 Intelligence. She also worked in competitive intelligence at WNS Global Services. Ms. Malhotra earned her master’s degree in pharmacy (quality assurance) from India’s Delhi Institute of Pharmaceutical Sciences and Research.
